Skip to content
Review

Regulatory T cells as drivers of CNS remyelination: neuro-immune cross-talk and comparative insights from mammalian and zebrafish models.

Sep 2026 · International Reviews of Immunology · pp. 1-16 · 0 citations · 114 references
Medicine

TL;DR

The goal of this review is to demonstrate how Tregs can promote regeneration by balancing a variety of underlying molecular and cellular processes, and to draw comparisons between the mechanisms used by regeneration-competent and non-competent species.

Abstract

Demyelination of the Central Nervous System (CNS) is a pathological process that causes the destruction of the myelin sheath, the insulating cover that protects the nerve fibres. This serves as one of the major attributes of numerous neurological disorders, such as Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Acute Disseminated Encephalomyelitis (ADEM), Myelin Oligodendrocyte Glycoprotein-related antibody disease (MOGAD), etc. It is usually initiated as an immune-mediated injury to myelin, followed by dysregulation of the immune system and ultimately failure of effective remyelination. Although oligodendrocytes in the CNS have some capacity for regeneration, the surrounding microenvironment severely inhibits their function, which results in a reduced regenerative outcome. Previously referred to as suppressor T cells, regulatory T cells (Tregs) are a subset of T cells that were traditionally thought to have an immunosuppressive function. However, it has just recently been shown that they directly contribute to regeneration and repair. The goal of this review is to demonstrate how Tregs can promote regeneration by balancing a variety of underlying molecular and cellular processes. Recent research shows that Tregs affect oligodendrocyte lineage progression, microglial and astrocytic responses, and the milieu around the demyelination site in order to perform remyelination. These effects are age-dependent and occur both temporally and geographically. In order to offer an evolutionary perspective on the conserved immune-mediated regenerative pathways that may be diminished in mammals and can be further investigated for therapeutic purposes, this review also aims to draw comparisons between the mechanisms used by regeneration-competent and non-competent species.

View source

Similar papers

Open access Oct 2026

Astrocyte-derived CXCL14 promotes oligodendrocyte differentiation and remyelination via ERK1/2 signaling: implications for multiple sclerosis therapeutics

Multiple sclerosis (MS) is a debilitating demyelinating disease of the central nervous system (CNS) in which progressive neurological disability is closely linked to the failure of endogenous remyelination. Reactive astrocytes are hallmarks of MS lesions, yet their functional role in myelin repair remains incomplet...

Ye Gong, Hong-Jie Zheng, Rui-Juan Su et al. · 0 citations
Review Open access Aug 2026

Tissue repair in the central nervous system: the epigenetic programming of regulatory T cells

Regulatory T cells are well known for their immunomodulatory role but also their regenerative function is increasingly recognized across multiple tissue types including skeletal muscle, lung and the central nervous system (CNS). In the CNS, Tregs have been shown to promote oligodendrocyte precursor cell differentiation...

Sarah Chenine, A. Tiane, P. Baeten et al. · 0 citations
Open access Aug 2026

Injury-transduced oligodendrocytes modulate neuroinflammation and glial activation in diseased and non-diseased central nervous system

It is shown that OLs respond to demyelinating diseases by increasing the expression and secretion of serine protease inhibitor clade A member 3N (SERPINA3N), and that SerpinOLs represent a common population of injury-transduced OLs that contributes to CNS pathology beyond myelin production.

Yan Wang, Mei-Na Zhu, Joohyun Park et al. · 0 citations
Review Open access Sep 2026

Stem Cell-Based Therapies for Central Nervous System Demyelinating Diseases: Clinical Evidence, Therapeutic Niches, and Translational Boundaries

Central nervous system demyelinating disorders differ substantially in pathobiology, reversibility, and capacity for tissue repair. Disease-modifying therapies can suppress inflammatory activity in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), but they do not replace lost oligodendrocytes...

Qian-Ping Luo, Dong-Gan Jin, Zhen-Ying Zhan · 0 citations
Open access Sep 2026

Fibronectin inhibition restores myelination in endothelial TNFR2-dependent nonremitting experimental autoimmune encephalomyelitis.

Therapeutically, systemic fibronectin inhibition restored regeneration and clinical remission, as well as prevented OPC accumulation at lesions, providing strong preclinical evidence for fibronectin-targeting therapies in MS and other demyelinating disorders.

Aikaterini Nanou, Konstantinos Apostolou-Karampelis, V. Triantafyllidou et al. · 0 citations
Review Open access Sep 2026

Why repair fails in AQP4-IgG-positive neuromyelitis optica spectrum disease: an astrocyte-centered framework for remyelination and neuroaxonal preservation

Aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disease (NMOSD) is an autoimmune astrocytopathy in which a single attack may cause permanent visual or neurological disability. Although targeted immunotherapies reduce relapse risk, they do not establish repair of previously injured tissue....

Wen-Jing Luo, Ning Peng, Si-Qian Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.